Loading...
XSHE
300485
Market cap674mUSD
Jul 10, Last price  
9.73CNY
1D
2.42%
1Q
-15.02%
Jan 2017
-54.56%
IPO
-36.11%
Name

Beijing Science Sun Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300485 chart
P/E
321.64
P/S
11.58
EPS
0.03
Div Yield, %
0.23%
Shrs. gr., 5y
0.28%
Rev. gr., 5y
-17.37%
Revenues
405m
-2.82%
245,023,222396,012,790480,212,178589,846,385607,138,310616,238,487749,986,8481,427,750,9431,190,902,5061,094,225,2801,050,805,0891,050,805,088734,546,852734,546,852476,569,580416,481,789404,718,439
Net income
15m
P
84,659,947132,566,730160,788,858202,571,534209,273,987258,405,895281,604,135283,107,053148,639,046154,903,459402,270,478402,270,480204,734,954204,734,957102,917,834-68,853,09614,570,990
CFO
27m
-80.09%
77,061,070151,933,363196,824,109214,225,147169,357,075212,893,474108,212,673146,516,272172,523,039263,725,621183,295,288110,434,54321,210,976135,973,94627,078,735
Dividend
May 29, 20240.022 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Science Sun Pharmaceutical Co., Ltd. is a company, established in 1999 and headquartered in Beijing, China, that operates within the Chinese pharmaceutical market. It is dedicated to the research, development, manufacturing, and distribution of injectable medications. The firm offers a wide array of products designed to treat conditions related to the cardiovascular, cerebrovascular, immunomodulatory, and nervous systems, among other health areas.
IPO date
Jun 26, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT